Clinical trial · Observational
Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
NCT07088354CI-TRIAL-00092688DL-ESCCrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to develop and validate a deep learning model to predict pathological complete response (pCR) in patients with esophageal squamous cell carcinoma who have undergone neoadjuvant immunochemotherapy. Clinical, imaging, and pathological data from previously treated patients will be collected and analyzed. The model is expected to assist in predicting treatment outcomes and guide personalized therapeutic strategies.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Deep Learning | — | UNRESOLVED | — |
| Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Neoadjuvant Immunochemotherapy | — | UNRESOLVED | — |
| Pathological Complete Response | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| The high-throughput extraction of large amounts of quantitative image features from medical images | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- ESCC Patients Undergoing Neoadjuvant Immunochemotherapy and Surgery
- description
- Patients with esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy followed by surgery.
- interventionNames
- Diagnostic Test: The high-throughput extraction of large amounts of quantitative image features from medical images
Primary outcomes (1)
- measure
- Pathological Complete Response (pCR) Rate
- timeFrame
- Assessed at the time of surgery, within 1 month post-treatment.
- description
- The proportion of patients achieving complete pathological remission after neoadjuvant immunochemotherapy followed by surgery.
Secondary outcomes (1)
- measure
- Model Performance Metrics (AUC, Accuracy, Sensitivity, Specificity, PPV, NPV)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pathologically confirmed esophageal squamous cell carcinoma (ESCC). 2. Received at least one cycle of neoadjuvant chemotherapy combined with immunotherapy. 3. Underwent contrast-enhanced chest CT before initiation of neoadjuvant treatment. 4. Underwent contrast-enhanced chest CT after completion of neoadjuvant treatment and prior to surgery. Exclusion Criteria: 1. Diagnosis of other malignancies. 2. Received other anti-tumor therapies before or during neoadjuvant chemo-immunotherapy. 3. Incomplete clinical data. 4. Poor-quality CT imaging.
References
Publications (0)
Data not yet available
No reference posted for this study.